Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
AAM Launches Further Broadside At Proposed Blocking Act
Proposed Act ‘Well-Intended But Misguided,’ AAM Claims
Dec 15 2020
•
By
Dean Rudge
Weakening the 180-day exclusivity incentive will delay patient access, the AAM insists • Source: Shutterstock
More from Policy & Regulation
More from Generics Bulletin